Abstract:SESSION TITLE: Chest Infections Posters 10 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/11/2023 12:00 pm - 12:45 pm PURPOSE: Mycobacterium avium complex lung disease (MACLD) is a serious pulmonary infection that can cause lung damage. Patients with refractory MACLD often still test positive for MAC infection after 6 months on guideline-based therapy. There are limited data on treatment patterns and healthcare resource utilization (HCRU) among patients with refractory MACLD in the US. The objective of this study was to assess HCRU among US patients with potentially refractory MACLD treatment patterns. METHODS: A retrospective study was conducted using managed care claims from the IBM® MarketScan® research database (2014.07-2020.06). Treated MACLD patients were those who received diagnosis and subsequent initial therapy of ≥28 days of concurrent macrolide with at least one other antibiotic (ethambutol, rifamycin, aminoglycoside, fluoroquinolone, oxazolidinone, diarylquinoline). The first 6 months of treatment was defined as the baseline regimen and the possible refractory date was the date 6 months after treatment initiation. Among patients treated for ≥18 months, treatment patterns indicating potentially refractory MACLD were defined as adding new drug classes after the 6-month baseline treatment. The proportion of refractory MACLD patients with hospitalizations (all-cause, respiratory-related, and NTMLD-related) was assessed at 6-month intervals for a total of 2 years after treatment initiation. RESULTS: The study identified 87 patients (7.5% of 1164 patients treated for MACLD) who showed potentially refractory treatment patterns during the 12-month period after the possible refractory date. Mean (SD) age at MACLD diagnosis was 62 (13) years; 70% were female. During the baseline period, 16% had gastroesophageal reflux disease; common pulmonary comorbidities included COPD (32%), bronchiectasis (29%), pneumonia (29%) and asthma (21%). All-cause and respiratory-related hospitalization rates were high (17% and 7%) during the 6-month baseline treatment period and continued to increase over the 2-year follow-up period, reaching 22% and 11% in months 19-24 after treatment initiation despite treatment of at least 18 months. Ethambutol and rifamycin were included in the baseline regimens of 85% and 82% of refractory patients, respectively. Fluoroquinolone was the most commonly added drug (by 77% of patients) in the 12-month post-refractory treatment period, followed by aminoglycoside (9%). CONCLUSIONS: Despite treatment of at least 1.5 years, patients with potentially refractory MACLD showed high hospitalization burden which remained high or increased over a 2-year follow-up period after treatment initiation. CLINICAL IMPLICATIONS: The increase in hospitalization burden observed after the 6-month initial treatment highlights the need for treatment monitoring and improved management among patients with refractory MACLD. DISCLOSURES: Employee relationship with Insmed Pharmaceuticals Please note: 4 years Added 03/24/2023 by Mariam Hassan, source=Web Response, value=Salary No relevant relationships by Matthew Lucci No relevant relationships by Bonny Shah Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present by Ping Wang, value=Salary Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present Added 03/23/2023 by Ping Wang, source=Web Response, value=Stocks No relevant relationships by Emily Welch Research relationship with Insmed Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with Paratek Please note: 24 months or more by Kevin Winthrop, value=Consulting fees Research relationship with Redhill Biopharma Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Grant/Research Support Consultant relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Consulting fee Consultant relationship with Spero Therapeutics Please note: 24 months or more by Kevin Winthrop, value=Consulting fee

Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient

[Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection]

Linezolid Combined with Trimethoprim-Sulfamethoxazole Therapy for the Treatment of Disseminated Nocardiosis.

Regimen comprising clarithromycin, clofazimine and bedaquiline is more efficacious than monotherapy in a mouse model of chronic lung infection

Role of fluorescence in situ hybridization in detecting mycobacterium avium complex presenting as fever in treatment failure HIV

R-CHOP Chemotherapy for Disseminated Mycobacterium avium Complex Disease due to Anti-Interferon-Gamma Autoantibodies: A Case Report

Disseminated Mycobacterium avium Infection with Different Clinical Presentation in Two Human Immunodeficiency Virus-positive Patients

Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients

How do I manage disseminated Mycobacterium avium complex disease in people with HIV?

Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy

Mycobacterium avium complex (MAC) infection in severely immunocompromised people living with HIV: Findings from a five-year cohort

Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection

The use of dual β-lactams to restore susceptibility of Mycobacterium avium complex

Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial

Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection

Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis

Treatment patterns and health care resource utilization among patients with potentially treatment-refractory mycobacterium avium complex lung disease in the united states

Linezolid and Rifampicin Combination to Combat Cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection

In Vitro Assessment of 17 Antimicrobial Agents Against Clinical Mycobacterium Avium Complex Isolates

[A Study on the Clinical Efficacy of a Combination Regimen with Levofloxacin and Capreomycin in the Treatment of Multi-Drug Resistant Pulmonary Tuberculosis].